Drug
Zanzalintinib clinical trials
Also written XL092.
Keep track of what changes. Save the zanzalintinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- XL092
- 47
Combined with it in one product
Studies by the year they started
45 studies that test it; most in 2026 (23); 2 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 15 |
| 2026 | 23 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 32
Exelixis (11) · M.D. Anderson Cancer Center (5) · Washington University School of Medicine (4) · Merck Sharp & Dohme LLC (3) · UNC Lineberger Comprehensive Cancer Center (2) · University of Texas Southwestern Medical Center (1) · Pedro Barata, MD, MSc (1) · Guru Sonpavde (1)
Often tested with
Tested in the same studies.
Pembrolizumab (5) · Nivolumab (4) · Atezolizumab (3) · Durvalumab (3) · Cemiplimab (2) · Tremelimumab (2) · Cabozantinib (1) · Abiraterone (1)
Studies
Open first, then newest update. How each study uses zanzalintinib is read from its arms, and is right about nine times in ten.
Testing it · 47
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsRecruitingPhase 2/3ExelixisNCT06943755Written as Zanzalintinib
- Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver CancerRecruitingPhase 1/2Devalingam MahalingamNCT07042919Written as Zanzalintinib
- A Study of Zanzalintinib in Participants With Recurrent or Progressive MeningiomaRecruitingPhase 2ExelixisNCT07428616Written as Zanzalintinib
- A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07489495Written as Zanzalintinib
- Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingPhase 1/2University of Texas Southwestern Medical CenterNCT07878689Written as Zanzalintinib
- Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid CancerNot yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07470489Written as Zanzalintinib
- Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)RecruitingPhase 2Washington University School of MedicineNCT06926634Written as Zanzalintinib
- XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue SarcomaRecruitingPhase 2Northwestern UniversityNCT06571734Written as Zanzalintinib
- Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine CancerRecruitingPhase 1Washington University School of MedicineNCT06795009Written as Zanzalintinib
- A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory NeuroblastomaNot yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07527169Written as Zanzalintinib
- XL092 and Cemiplimab in BRAF WT Thyroid CancerRecruitingPhase 1UNC Lineberger Comprehensive Cancer CenterNCT06902376Written as XL092
- Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT07049926Written as Zanzalintinib
- Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)Not yet recruitingPhase 2ExelixisNCT07845786Written as Zanzalintinib
- A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)RecruitingPhase 2M.D. Anderson Cancer CenterNCT07193550Written as Zanzalintinib
- Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual DiseaseRecruitingPhase 3ExelixisNCT07750158Written as Zanzalintinib
- Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate CancerNot yet recruitingPhase 2Pedro Barata, MD, MScNCT07608718Written as Zanzalintinib
- Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable MetastasisRecruitingPhase 2Qian QinNCT06794229Written as Zanzalintinib
- Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before SurgeryRecruitingPhase 2M.D. Anderson Cancer CenterNCT06959511Written as Zanzalintinib
- Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior TherapyNot yet recruitingPhase 2Guru SonpavdeNCT07185945Written as Zanzalintinib
- H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)Not yet recruitingPhase 2UNC Lineberger Comprehensive Cancer CenterNCT07484139Written as XL092
See all 47 studies that test zanzalintinib →
Given in every arm · 4 — zanzalintinib is usual care beside what is tested
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsRecruitingPhase 1ExelixisNCT05176483Written as Zanzalintinib
- Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCCRecruitingPhase 2Karie RuncieNCT06863311Written as XL092
- Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)TerminatedPhase 1ExelixisNCT06191796Written as zanzalintinib
- A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsActive, not recruitingPhase 1ExelixisNCT03845166Written as XL092
Codes
What other systems call zanzalintinib · ClinicalTrials.gg INT017046
- UNII (FDA) KC2JC2ZA04ZANZALINTINIBConfirmed FDA, Wikidata
- Wikidata Q124353001zanzalintinibConfirmed FDA, Wikidata
- NCI Thesaurus C161598ZanzalintinibOne source FDA
- DrugBank DB17525One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KC2JC2ZA04 | ZANZALINTINIB | Confirmed FDA, Wikidata |
| Wikidata | Q124353001 | zanzalintinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C161598 | Zanzalintinib | One source FDA |
| DrugBank | DB17525 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.